RT Journal Article
SR Electronic
T1 Pre-referral rectal artesunate and referral completion among children with suspected severe malaria in the Democratic Republic of the Congo, Nigeria and Uganda
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.27.21264073
DO 10.1101/2021.09.27.21264073
A1 Brunner, Nina C.
A1 Omoluabi, Elizabeth
A1 Awor, Phyllis
A1 Okitawutshu, Jean
A1 Tshefu, Antoinette
A1 Signorell, Aita
A1 Akano, Babatunde
A1 Ayodeji, Kazeem
A1 Okon, Charles
A1 Yusuf, Ocheche
A1 Athieno, Proscovia
A1 Kimera, Joseph
A1 Tumukunde, Gloria
A1 Angiro, Irene
A1 Kalenga, Jean-Claude
A1 Delvento, Giulia
A1 Lee, Tristan T.
A1 Lambiris, Mark
A1 Ross, Amanda
A1 Cereghetti, Nadja
A1 Visser, Theodoor
A1 Napier, Harriet G.
A1 Buj, Valentina
A1 Burri, Christian
A1 Lengeler, Christian
A1 Hetzel, Manuel W.
YR 2021
UL http://medrxiv.org/content/early/2021/12/16/2021.09.27.21264073.abstract
AB Background Children who receive pre-referral rectal artesunate (RAS) require urgent referral to a health facility where appropriate treatment for severe malaria can be provided. However, the rapid improvement of a child’s condition after RAS administration may influence a caregiver’s decision to follow this recommendation. Currently, the evidence on the effect of RAS on referral completion is limited. In this study, we investigated the relationship between RAS implementation and administration and referral completion.Methods and Findings An observational study accompanied the roll-out of RAS in three malaria endemic settings in the Democratic Republic of the Congo (DRC), Nigeria and Uganda. Community health workers and primary health centres enrolled children under five years with suspected severe malaria before and after the roll-out of RAS. All children were followed up 28 days after enrolment to assess their treatment seeking pathways, treatments received, and their health outcome. In total, 8,365 children were enrolled, 77% of whom fulfilled all inclusion criteria and had a known referral completion status. Referral completion was 67% (1,408/2,104) in DRC, 48% (287/600) in Nigeria and 58% (2,170/3,745) in Uganda. In DRC and Uganda, RAS users were less likely to complete referral than RAS non-users in the pre-roll-out phase (adjusted odds ratio [aOR] = 0.48, 95% CI 0.30–0.77 and aOR = 0.72, 95% CI 0.58–0.88, respectively). Among children seeking care from a primary health centre in Nigeria, RAS users were less likely to complete referral compared to RAS non-users in the post-roll-out phase (aOR = 0.18, 95% CI 0.05–0.71). In Uganda, among children who completed referral, RAS users were significantly more likely to complete referral on time than RAS non-users enrolled in the pre-roll-out phase (aOR = 1.81, 95% CI 1.17–2.79).Conclusions The findings of this study raise legitimate concerns that the roll-out of RAS may lead to lower referral completion in children who were administered pre-referral RAS. To ensure that community-based programmes are effectively implemented, barriers to referral completion need to be addressed at all levels. Alternative effective treatment options should be provided to children unable to complete referral.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03568344Funding StatementThis study was funded by Unitaid (grant reference XM-DAC-30010-CHAIRAS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Review Committee of the World Health Organization (WHO ERC, No. ERC.0003008) Ethics Committee of the University of Kinshasa School of Public Health (No. 012/2018) Health Research Ethics Committee of the Adamawa State Ministry of Health (S/MoH/1131/I) National Health Research Ethics Committee of Nigeria (NHREC/01/01/2007-05/05/2018) Higher Degrees, Research and Ethics Committee of the Makerere University School of Public Health (No. 548) Uganda National Council for Science and Technology (UNCST, No. SS 4534) Scientific and Ethical Review Committee of CHAI (No. 112, 21 Nov 2017)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual de-identified participant data that underlie the results reported in this article are available at zenodo.org upon reasonable request (DOI: 10.5281/zenodo.5570278).